Megan Barnet

Dr. Megan Barnet

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
MBMegan Barnet
Megan Barnet
SOSandra O’tOole
Sandra O’tOole
LHLisa G. Horvath
Lisa G. Horvath
CSChristina Selinger
Christina Selinger
BYBing Yu
Bing Yu
SKSteven Kao
Steven Kao

1 September 2021 in Clinical Lung Cancer
Verified
Journal Article
Closed access
ADAlexander Davis
Alexander Davis
AMAnnabelle Mahar
Annabelle Mahar
KWKirby Wong
Kirby Wong
MBMegan Barnet
Megan Barnet
SKSteven Kao
Steven Kao

14 July 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
ACAdrian Chye
Adrian Chye
IAIndia Allen
India Allen
MBMegan Barnet
Megan Barnet
DBDeborah L. Burnett
Deborah L. Burnett
Blockade of immune checkpoints transformed the paradigm of systemic cancer therapy, enabling substitution of a cytotoxic chemotherapy backbone to one of immunostimulation in many settings. Invigorating host immune cells against tumor neo-antigens, however, can induce severe autoimmune toxicity which in many cases requires ongoing management. Many immune-related adverse events (irAEs) are clinically and pathologically indistinguishable from inborn errors of immunity arising from genetic polymorphisms of immune checkpoint genes, suggesting a possible shared driver for both conditions. Many endocrine irAEs, for example, have analogous primary genetic conditions with varied penetrance and severity despite consistent genetic change. This is akin to onset of irAEs in response to immune checkpoint inhibitors (ICIs), which vary in timing, severity and nature despite a consistent drug target. Host contribution to ICI response and irAEs, particularly those of endocrine origin, such as thyroiditis, hypophysitis, adrenalitis and diabetes mellitus, remains poorly defined. Improved understanding of host factors contributing to ICI outcomes is essential for tailoring care to an individual’s unique genetic predisposition to response and toxicity, and are discussed in detail in this review.

Verified
Journal Article
Open access
PDF file
MBMegan Barnet
Megan Barnet
WCWendy Cooper
Wendy Cooper
MBMichael Boyer
Michael Boyer
SKSteven Kao
Steven Kao
Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where “best-case” scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice.

4 June 2018 in BioEssays
Verified
Journal Article
Closed access
PDF file
MBMegan Barnet
Megan Barnet
PBPrunella Blinman
Prunella Blinman
WCWendy Cooper
Wendy Cooper
MBMichael J. Boyer
Michael J. Boyer
SKSteven Kao
Steven Kao
CGChristopher C. Goodnow
Christopher C. Goodnow

1 January 2018 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
MBMegan Barnet
Megan Barnet
RZRobert R. Zielinski
Robert R. Zielinski
AWAnne Warby
Anne Warby
CLCraig R. Lewis
Craig R. Lewis
SKSteven Kao
Steven Kao